1 Chappell LC,Bell JL,Smith A,et al.Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy(PITCHES):a randomised controlled trial.Lancet,2019,394:849-860. 2 冯燕,马小莲,马晨涵,等.妊娠期肝内胆汁淤积症患者肝脏代谢水平及危险因素分析.中国妇幼保健,2021,36:976-979. 3 Deniz CD,Ozler S,Sayın FK.Association of adverse outcomes of intrahepatic cholestasis of pregnancy with zonulin levels.J Obstet Gynaecol,2021,41:904-909. 4 任松.腺苷蛋氨酸联合糖皮质激素治疗高龄产妇妊娠期肝内胆汁淤积症的疗效及对产妇肝功能指标的影响.中国妇幼保健,2019,34:258-261. 5 刘影林,黄燕.多囊卵巢综合征患者血清miR-155、 IL-6水平与IVF-ET妊娠结局的关系.标记免疫分析与临床,2021,28:2029-2032,2049. 6 谢艳华,高岩,何雪莲.妊娠期肝内胆汁淤积症患者血清中miR-21和IGFBP-3的表达及与围生儿结局的关系.国际妇产科学杂志,2019,46:503-506. 7 谢幸,苟文丽.妇产科学.第8版.北京:人民卫生出版社,2013. 8 Smith DD,Rood KM.Intrahepatic Cholestasis of Pregnancy.Clin Obstet Gynecol,2020,63:134-151. 9 王磊,徐涛,宋传东,等.基于深度学习的miRNA与疾病相关性预测算法.电子学报,2020,48:870-877. 10 Fiori LM,Kos A,Lin R,et al.miR-323a regulates ERBB4 and is involved in depression.Mol Psychiatry,2021,26:4191-4204. 11 左江成,刘美,耿顺康,等.miR-155在乳腺癌患者组织和血浆中的表达水平及临床意义.中国妇幼保健,2019,34:438-442. 12 赵琳琳,胡春杨,刘倩.miR-155和SMAD4表达水平与宫颈癌放疗敏感性及预后的关系.热带医学杂志,2020,20:721-725. 13 Luo D,Wu WX,Pan YN,et al.Associations of prenatal exposure to per- and polyfluoroalkyl substances with the neonatal birth size and hormones in the growth hormone/insulin-like growth factor axis.Environ Sci Technol,2021,55:11859-11873. 14 Liao S,Vickers MH,Taylor RS,et al.Maternal serum IGF-1,IGFBP-1 and 3,and placental growth hormone at 20weeks' gestation in pregnancies complicated by preeclampsia.Pregnancy Hypertens,2017,10:149-154. 15 殷欣欣,崔照领,马丽静,等.IGF-2、IGFBP-3在胎儿生长受限患者胎盘组织中的表达及其临床意义.生殖医学杂志,2021,30:377-383. 16 El Tayebi HM,Waly AA,Assal RA,et al.Transcriptional activation of the IGF-II/IGF-1R axis and inhibition of IGFBP-3 by miR-155 in hepatocellular carcinoma.Oncol Lett,2015,10:3206-3212. 17 金嫔嫔,仇春波,叶黎霞,等.妊娠期肝内胆汁淤积症发生的危险因素和对妊娠结局的影响.中国妇幼保健,2021,36:3581-3583. 18 谢芝芳,陆丹.妊娠期肝内胆汁淤积症患者不同血清总胆汁酸水平对不良妊娠结局的影响.中国妇幼保健,2021,36:4219-4221. 19 赵临潇,左博云,李静亚,等.妊娠期肝内胆汁淤积症孕妇胎盘ABCB4基因表达与妊娠结局的关系.海南医学,2022,33:1424-1427.
